About us
The founding team combines advanced scientific expertise in chemistry, biology, and bioinformatics.
Currently, BrightMol consists of four partners and colleagues who have been working together daily for years.
We are currently seeking a seed fund to accelerate the development of our platform,
expand our research and development capabilities,
and bring our innovative drug discovery solutions to market.
Services
BrightMol addresses the limitations in the development of
degraders with an innovative platform designed specifically to accelerate drug discovery.
The technology allows for the rapid, precise, and specific monitoring of the degradation
action of malfunctioning proteins in certain diseases.
It also enables the evaluation of the activity of classical inhibitors developed using
traditional pharmacological approaches, enhancing its versatility.
